Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Adaptimmune Therapeutics's operating cash flow for the twelve months ending Jun 30, 2025 was -$190.03M. For fiscal 2024 it was -$73.21M. The highest annual figure on record is $36.84M in fiscal 2014.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$73.21M | – |
| FY2023 | Dec 31, 2023 | -$140.88M | – |
| FY2022 | Dec 31, 2022 | -$141.77M | -1421.4% |
| FY2021 | Dec 31, 2021 | $10.73M | – |
| FY2020 | Dec 31, 2020 | -$53.59M | – |
| FY2019 | Dec 31, 2019 | -$112.51M | – |
| FY2018 | Dec 31, 2018 | -$104.39M | – |
| FY2017 | Dec 31, 2017 | -$54.32M | – |
| FY2015 | Jun 30, 2015 | -$29.67M | -180.5% |
| FY2014 | Jun 30, 2014 | $36.84M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$34.78M | -173.4% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$66.59M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$34.20M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$54.45M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $47.40M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$31.95M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$14.68M | -818.7% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$45.16M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$43.76M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$37.28M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $2.04M | -98.5% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$48.16M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$41.25M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$54.40M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $133.93M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$45.20M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$31.46M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$46.54M | -376.1% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$29.22M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$16.32M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$24.92M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $16.86M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$12.53M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$29.61M | -397.9% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$34.17M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$36.20M | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$31.69M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $9.94M | -26.3% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$35.36M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$47.28M | – |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -$21.36M | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $13.49M | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | -$18.01M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | -$28.44M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -$5.64M | – |
See a number that looks wrong?